+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Metastatic Pancreatic Cancer (MPC) - Pipeline Insight, 2020

  • PDF Icon

    Clinical Trials

  • 106 Pages
  • February 2020
  • Region: Global
  • DelveInsight
  • ID: 4989370

Metastatic Pancreatic Cancer (MPC) Overview

"Metastatic Pancreatic Cancer (MPC) Pipeline Insight, 2020" report outlays comprehensive insights of present clinical development scenario and growth prospects across the Metastatic Pancreatic Cancer (MPC) market. A detailed picture of the Metastatic Pancreatic Cancer (MPC) pipeline landscape is provided, which includes the disease overview and Metastatic Pancreatic Cancer (MPC) treatment guidelines. The assessment part of the report embraces in-depth Metastatic Pancreatic Cancer (MPC) commercial assessment and clinical assessment of the Metastatic Pancreatic Cancer (MPC) pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Metastatic Pancreatic Cancer (MPC) collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

Metastatic Pancreatic Cancer (MPC) of pipeline development activities

The report provides insights into:

  • All of the companies that are developing therapies for the treatment of Metastatic Pancreatic Cancer (MPC) with aggregate therapies developed by each company for the same.
  • Different therapeutic candidates segmented into early-stage, mid-stage and late stage of development for the Metastatic Pancreatic Cancer (MPC) treatment.
  • Metastatic Pancreatic Cancer (MPC) key players involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of Metastatic Pancreatic Cancer (MPC) market.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university web sites and industry-specific third-party sources, etc.  

Metastatic Pancreatic Cancer (MPC) Analytical Perspective

In-depth Metastatic Pancreatic Cancer (MPC) Commercial Assessment of products

This report provides a comprehensive commercial assessment of therapeutic drugs that have been included, which comprises of collaborations, licensing, and acquisition deal value trends. The report also covers company-company collaborations (licensing/partnering), company-academia collaborations, and acquisition analysis in both graphical and tabulated form in a detailed manner.

Metastatic Pancreatic Cancer (MPC) Clinical Assessment of products

The report comprises of comparative clinical assessment of products by development stage, product type, route of administration, molecule type, and MOA type across this indication.

Scope of the report

  • The Metastatic Pancreatic Cancer (MPC) report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Metastatic Pancreatic Cancer (MPC) across the complete product development cycle, including all clinical and nonclinical stages.
  • It comprises of detailed profiles of Metastatic Pancreatic Cancer (MPC) therapeutic products with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details
  • Detailed Metastatic Pancreatic Cancer (MPC) research and development progress and trial details, results wherever available, are also included in the pipeline study.
  • Coverage of dormant and discontinued pipeline projects along with the reasons if available across Metastatic Pancreatic Cancer (MPC).

Report Highlights

  • A better understanding of disease pathogenesis contributing to the development of novel therapeutics for Metastatic Pancreatic Cancer (MPC).    
  • In the coming years, the Metastatic Pancreatic Cancer (MPC) market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics that are working to assess challenges and seek opportunities that could influence Metastatic Pancreatic Cancer (MPC) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • A detailed portfolio of major pharma players who are involved in fueling the Metastatic Pancreatic Cancer (MPC) treatment market. Several potential therapies for Metastatic Pancreatic Cancer (MPC) are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Metastatic Pancreatic Cancer (MPC) market size in the coming years.  
  • Our in-depth analysis of the pipeline assets (in early-stage, mid-stage and late stage of development for the treatment of Metastatic Pancreatic Cancer (MPC) ) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Key Questions

  • What are the current options for Metastatic Pancreatic Cancer (MPC) treatment?
  • How many companies are developing therapies for the treatment of Metastatic Pancreatic Cancer (MPC)?
  • What are the principal therapies developed by these companies in the industry?
  • How many therapies are developed by each company for the treatment of Metastatic Pancreatic Cancer (MPC)?
  • How many Metastatic Pancreatic Cancer (MPC) emerging therapies are in early-stage, mid-stage, and late stage of development for the treatment of Metastatic Pancreatic Cancer (MPC)?
  • Out of total pipeline products, how many therapies are given as a monotherapy and in combination with other therapies?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, and major licensing activities that will impact Metastatic Pancreatic Cancer (MPC) market?
  • Which are the dormant and discontinued products and the reasons for the same?
  • What is the unmet need for current therapies for the treatment of Metastatic Pancreatic Cancer (MPC)?  
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing Metastatic Pancreatic Cancer (MPC) therapies?
  • What are the clinical studies going on for Metastatic Pancreatic Cancer (MPC) and their status?
  • What are the results of the clinical studies and their safety and efficacy?
  • What are the key designations that have been granted for the emerging therapies for Metastatic Pancreatic Cancer (MPC)?
  • How many patents are granted and pending for the emerging therapies for the treatment of Metastatic Pancreatic Cancer (MPC)?

Table of Contents

1. Report Introduction
2. Metastatic Pancreatic Cancer (MPC)
2.1. Overview
2.2. History
2.3. Metastatic Pancreatic Cancer (MPC)
  • Symptoms
2.4. Causes
2.6. Metastatic Pancreatic Cancer (MPC)
  • Diagnosis
2.6.1. Diagnostic Guidelines
3. Metastatic Pancreatic Cancer (MPC)
  • Current Treatment Patterns
3.1. Metastatic Pancreatic Cancer (MPC)
  • Treatment Guidelines

4. Metastatic Pancreatic Cancer (MPC)
  • Analytical Perspective
4.1. In-depth Commercial Assessment
4.1.1. Metastatic Pancreatic Cancer (MPC)
  • Companies collaborations, Licensing, Acquisition - Deal Value Trends Assessment Summary
4.1.2. Metastatic Pancreatic Cancer (MPC)
  • Collaboration Deals Company-Company Collaborations (Licensing / Partnering) Analysis Company-University Collaborations (Licensing / Partnering) Analysis Metastatic Pancreatic Cancer (MPC)
  • Acquisition Analysis

5. Therapeutic Assessment
5.1. Clinical Assessment of Pipeline Drugs
5.1.1. Assessment by Phase of Development
5.1.2. Assessment by Product Type (Mono / Combination) Assessment by Stage and Product Type
5.1.3. Assessment by Route of Administration Assessment by Stage and Route of Administration
5.1.4. Assessment by Molecule Type Assessment by Stage and Molecule Type
5.1.5. Assessment by MOA Assessment by Stage and MOA
5.1.6. Assessment by Target Assessment by Stage and Target
6. Metastatic Pancreatic Cancer (MPC)
  • Late Stage Products (Phase-III)

7. Metastatic Pancreatic Cancer (MPC)
  • Mid Stage Products (Phase-II)

8. Early Stage Products (Phase-I)9. Pre-clinical Products and Discovery Stage Products10. Inactive Products11. Dormant Products
12. Metastatic Pancreatic Cancer (MPC)
  • Discontinued Products

13. Metastatic Pancreatic Cancer (MPC)
  • Product Profiles
13.1. Drug Name: Company
13.1.1. Product Description Product Overview Mechanism of action
13.1.2. Research and Development Clinical Studies
13.1.3. Product Development Activities Collaboration Agreements Acquisition Patent Detail
13.1.4. Tabulated Product Summary General Description Table
14. Metastatic Pancreatic Cancer (MPC)
  • Key Companies

15. Metastatic Pancreatic Cancer (MPC)
  • Key Products

16. Dormant and Discontinued Products
16.1. Dormant Products
16.1.1. Reasons for being dormant
16.2. Discontinued Products
16.2.1. Reasons for the discontinuation
17. Metastatic Pancreatic Cancer (MPC)
  • Unmet Needs

18. Metastatic Pancreatic Cancer (MPC)
  • Future Perspectives

19. Metastatic Pancreatic Cancer (MPC)
  • Analyst Review

20. Appendix
21. Report Methodology
21.1. Secondary Research
21.2. Expert Panel Validation